Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Ergomed plc is a UK-based pharmaceutical services company specializing in providing integrated services to the biotech and pharmaceutical industries, particularly in the areas of drug development and post-approval services. Its unique competitive advantage lies in its strong expertise in rare diseases and oncology, which positions it favorably in a niche market with high demand for specialized services.
Ergomed generates revenue primarily through contract research services, focusing on clinical trials and post-marketing surveillance. The company's strong relationships with biotech firms and its expertise in rare diseases provide it with pricing power and a competitive edge in securing contracts.
New contract wins in rare disease studies
Expansion of pharmacovigilance services in Europe
Regulatory approvals for clinical trials
Market demand for specialized biotech services
Regulatory changes impacting clinical trial processes
Technological disruption in drug development methodologies
Increased competition from larger CROs
Emergence of new entrants in the biotech services market
Low liquidity due to minimal operating cash flow
Potential for increased costs if revenue growth does not meet expectations
moderate - The demand for clinical research services can be affected by overall healthcare spending, which is influenced by economic conditions.
Interest rates affect Ergomed's cost of capital; however, with low debt levels (Debt/Equity of 0.03), the impact is minimal on financing costs.
minimal - Ergomed operates with low debt levels, reducing its sensitivity to credit market fluctuations.
growth - Investors are likely attracted to Ergomed due to its strong revenue growth and niche market focus.
moderate - Historical volatility has been moderate, reflecting the company's growth trajectory and market conditions.